

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM755790

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
BIOPHARMA CREDIT PLC		09/16/2022	Public Limited Company: ENGLAND AND WALES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	SAREPTA THERAPEUTICS, INC.		
<b>Street Address:</b>	215 First Street		
<b>City:</b>	Cambridge		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02142		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5115025	EXONDYS	
<b>Registration Number:</b>	5134619	EXONDYS 51	
<b>Registration Number:</b>	6059005	EXONDYS 51 ETEPLIRSEN INJECTION	
<b>Registration Number:</b>	5490967	EXONDYS 51 ETEPLIRSEN INJECTION	
<b>Serial Number:</b>	88314190	VYONDYS	
<b>Serial Number:</b>	88569849	VYONDYS 53	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6172359493		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	212-841-0406		
<b>Email:</b>	melissa.karasavidis@ropesgray.com		
<b>Correspondent Name:</b>	Melissa Karasavidis, Ropes & Gray LLP		
<b>Address Line 1:</b>	1211 Avenue of the Americas		
<b>Address Line 4:</b>	New York, NEW YORK 10036-8704		
<b>ATTORNEY DOCKET NUMBER:</b>	109585-0101		
<b>NAME OF SUBMITTER:</b>	Melissa Karasavidis		
<b>SIGNATURE:</b>	/Melissa Karasavidis/		
<b>DATE SIGNED:</b>	09/16/2022		

CH \$165.00 5115025

**Total Attachments: 5**

source=Sarepta - Trademark Release - Pharmakon (Akin Gump) (Executed)#page1.tif

source=Sarepta - Trademark Release - Pharmakon (Akin Gump) (Executed)#page2.tif

source=Sarepta - Trademark Release - Pharmakon (Akin Gump) (Executed)#page3.tif

source=Sarepta - Trademark Release - Pharmakon (Akin Gump) (Executed)#page4.tif

source=Sarepta - Trademark Release - Pharmakon (Akin Gump) (Executed)#page5.tif

## TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of September 16, 2022 (this “Termination and Release”) is made by BIOPHARMA CREDIT PLC, as collateral agent for the Lenders and the other Secured Parties (in such capacity, the “Collateral Agent”), in favor of SAREPTA THERAPEUTICS, INC. (the “Grantor”).

### RECITALS:

WHEREAS, the Grantor is a party to that certain Guaranty and Security Agreement, dated as of December 20, 2019 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”; terms used in this Termination and Release and not otherwise defined herein have the meanings set forth in the Guaranty and Security Agreement), by and among the Grantor, the other grantors party thereto, and the Collateral Agent pursuant to which each Grantor granted a security interest to the Collateral Agent in the Trademark Collateral (as defined below), including, but not limited to, those Trademarks listed on Schedule A hereto;

WHEREAS, the Grantor entered into that certain Trademark Security Agreement, dated as of December 20, 2019, as amended on July 2, 2020 pursuant to that certain Amendment No. 1 to Trademark Security Agreement (the “Trademark Security Agreement”), granting the Collateral Agent security interests in and liens on certain trademarks described therein (the “Trademark Collateral”);

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office (“USPTO”) on December 23, 2019 at Reel/Frame 6824/0251;

WHEREAS, Amendment No. 1 to Trademark Security Agreement was recorded with the USPTO on July 9, 2020 at Reel/Frame 6994/0880;

WHEREAS, the Grantor has requested that the Collateral Agent enter into this Termination and Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Collateral Agent may have in the Trademark Collateral pursuant to the Trademark Security Agreement; and

WHEREAS, the Collateral Agent desires to terminate and release its security interest in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees:

**SECTION 1. Release of Security Interest.** The Collateral Agent hereby (i) releases, terminates and discharges all liens and security interests the Collateral Agent has in, to and under the Trademark Collateral under the Trademark Security Agreement and (ii) reassigns, grants and conveys to the Grantor, without any representation or warranty of any kind, any and all of the Collateral Agent’s right, title and interest to the Trademark Collateral.

SECTION 2. Filing the Release. The Collateral Agent authorizes and requests that this Termination and Release be filed and recorded at the USPTO at the Grantor's sole cost and expense.

SECTION 3. Counterparts; Electronic Transmission. This Termination and Release may be executed and delivered by facsimile or other means of electronic transmission and such transmission shall constitute an original for all purposes.

SECTION 4. Governing Law. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.


*[Signature Page Follows]*

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

BIOPHARMA CREDIT PLC,  
as Collateral Agent



By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By:   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member

Schedule A  
Trademark Collateral

**Owned Trademarks**

Ref.	Status	Country Name	Mark	Date Filed	Serial No.	Registration Number	Issued Date
7017.US00	Registered	United States of America	EXONDYS	24-Oct-2014	86/433,761	5115025	03-Jan-2017
7019.US00	Registered	United States of America	EXONDYS 51	15-Jan-2016	86/876376	5134619	31-Jan-2017
7020.US00	Registered	United States of America	EXONDYS 51 ETEPLIRSEN INJECTION and Design 	19-Sep-2016	87/175,636	6059005	19-May-2020
7020.US01	Registered	United States of America	EXONDYS 51 ETEPLIRSEN INJECTION and Design 	23-Oct-2017	87/656,211	5490967	12-Jun-2018
7036.US00	Pending	United States of America	VYONDYS	25-Feb-2019	88/314,190		
7038.US00	Pending	United States of America	VYONDYS 53	07-Aug-2019	88/569,849		

**Licensed Trademarks**

None